MedTrace Logo

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271410 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-04-18

No results posted yet for this study

Summary

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

Conditions

  • Leukemia
  • Lymphoma, Large B-Cell, Diffuse
  • Leukemia, B-cell
  • Lymphoma, B-Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

BIOLOGICAL

CD19 CAR-T cells

CD19 CAR-T cell therapy

Sponsors & Collaborators

  • Chongqing Precision Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Sanbin Wang, MD · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

  • Cheng Qian, PhD · Chongqing University Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2023-12-31
Completion
2024-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04271410 on ClinicalTrials.gov